The influence of continuous perioperative beta-blocker therapy [esmolol] in combination with phosphodiesterase inhibition [enoximone] on cardiac neurohormonal activation and myocardial ischaemia in high-risk vascular surgery patients

Trial Profile

The influence of continuous perioperative beta-blocker therapy [esmolol] in combination with phosphodiesterase inhibition [enoximone] on cardiac neurohormonal activation and myocardial ischaemia in high-risk vascular surgery patients

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2009

At a glance

  • Drugs Enoximone (Primary) ; Esmolol (Primary)
  • Indications Myocardial ischaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 May 2007 Status change from recruiting to completed.
    • 28 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top